Checkpoint Kinase 2 (CHEK2) Mutation in Renal Cell Carcinoma: A Single-Center Experience

Main Article Content

Joanna Huszno
Zofia Kołosza

Keywords

checkpoint kinase 2 mutation, CHEK2 mutation, renal cell carcinoma, retrospective study, second neoplasm

Abstract

Renal cell carcinoma (RCC) occurs in sporadic and heritable forms. Genetic mutations have been identified as risk factors in 1–2% of RCC. The aim of this study was to evaluate I157T and CHEK2*1100delC mutations of checkpoint kinase 2 (CHEK2) gene in RCC. Medical records of 40 clear cell RCC patients who had genetic tests and consultation at the Genetic Outpatient Clinic, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Poland, were reviewed retrospectively. Mutation profile was assessed by ASA-PCR and RFLP-PCR techniques. Only three female patients had CHEK2 mutation (I157T). No CHEK2*1100delC was observed in any of the patients. These tumors were N0, and two were Grade 3. One showed capsular infiltration. No blood vessel infiltration or metastases was observed. Overall, RCC from patients with CHEK2 mutation did not display any special characteristics when compared with those without the mutation. While no association between CHEK2 mutation and RCC could be established, all three patients with CHEK2 mutation developed second neoplasms many years after first diagnosis. Further studies, especially regarding CHEK2 mutation as a predictive factor for second neoplasm in RCC patients, are warranted.

Abstract 2205 | PDF Downloads 926 HTML Downloads 1115 XML Downloads 554

References

1. Borkowski A, Czaplicki M. Nowotwory i torbiele nerek. Wyd 1. PZWL; Warszawa 2002.
2. Goldman SM, Fishman EK, Abeshouse G, Cohen JH. Renal cell carcinoma diagnosed in three generations of a single family. South Med J. 1979;72:1457–9. http://dx.doi.org/10.1097/00007611-197911000-00031
3. Krzystolik K, Cybulski C, Lubiński J, Zajączek S, Sochańska M, Tołoczko A, et al. Wczesna diagnostyka bezobjawowych raków nerek w rodzinach z zespołem von Hippel-Lindau w Polsce. Urol Pol. 1998;51:171–81.
4. Neumann HP. Basic criteria for clinical diagnosis and genetic counseling in von Hippel-Lindau syndrome. J Vasc Dis. 1987;16:220–6.
5. Marston Linehan W, Srinivasan R, Schmidt LS. The genetic basis of kidney cancer: A metabolic disease. Nat Rev Urol. 2010 May;7(5):277–85. http://dx.doi.org/10.1038/nrurol.2010.47
6. Marston Linehan W. Genetic basis of kidney cancer: Role of genomics for the development of disease-based therapeutics. Genome Res. 2012 Nov;22(11):2089–100. http://dx.doi.org/10.1101/gr.131110.111
7. Hale V, Weischer M, Park JY. CHEK2*1100delC Mutation and risk of prostate cancer. Hindawi Publish Corp Prostate Cancer. 2014;2014:294575, 1–9. http://dx.doi.org/10.1155/2014/294575
8. Liu C, Wang Y, Wang QS, Wang YJ. The CHEK2 I157T variant and breast cancer susceptibility: A systematic review and meta-analysis. Asian Pac J Cancer Prev. 2012;4:1355–60. http://dx.doi.org/10.7314/APJCP.2012.13.4.1355
9. Cybulski C, Górski B, Huzarski T, Masojć B, Mierzejewski M, Debniak T, et al. CHEK2 Is a multiorgan cancer susceptibility gene. Am J Hum Genet. 2004 Dec;75(6):1131–5. http://dx.doi.org/10.1086/426403
10. Huszno J, Budryk M, Kołosza Z, Tęcza K, Pamuła Piłat J, Nowara E, et al. Comparison between CHEK2*1100delC/I157T mutation carrier and noncarrier breast cancer patients: A clinicopathological analysis. Oncology. 2016;90(4):193–8. http://dx.doi.org/10.1159/000444326
11. Easton D, McGuffog L, Thompson D, Dunning A, Tee L, Baynes C, et al. CHEK2*1100delC and susceptibility to breast cancer: A collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. Am J Hum Genet. 2004 Jun;74(6):1175–82. http://dx.doi.org/10.1086/421251
12. Zhang S, Phelan CM, Zhang P, Rousseau F, Ghadirian P, Robidoux A, et al. Frequency of the CHEK2 1100delC mutation among women with breast cancer: An international study. Cancer Res. 2008;68(7):200. http://dx.doi.org/10.1158/0008-5472.CAN-07-5187
13. Cybulski C, Wokołorczyk D, Jakubowska A, Huzarski H, Byrski T, Gronwald J, et al. Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer. J Clin Oncol. 2011;29:3747–52. http://dx.doi.org/10.1200/JCO.2010.34.0778
14. Weischer M, Bojesen SE, Tybjærg-Hansen A, Axelsson ChK, Nordestgaard BG. Increased risk of breast cancer associated with CHEK2*1100delC. J Cancer Oncol. 2007;25(1):57–63.
15. Weischer M, Bojesen SE, Ellervik Ch, Tybjærg-Hansen A, Nordestgaard BG. CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: Meta-analyses of 26,000 patient cases and 27,000 controls. J Clin Oncol. 2008;26(4):542–8. http://dx.doi.org/10.1200/JCO.2007.12.5922
16. Cybulski C, Wokolorczyk D, Kladny J, Kurzawski G, Kurzwaski G, Suchy J, et al. Germline CHEK2 mutations and colorectal cancer risk: Different effects of a missense and truncating mutations? Eur J Hum Genet. 2007;15(2):237–41. http://dx.doi.org/10.1038/sj.ejhg.5201734
17. Kilpivaara O, Alhopuro P, Vahteristo P, Aaltonen LA, Nevanlinna H. CHEK2 I157T associates with familial and sporadic colorectal cancer. J Med Genet. 2006;43:e34. http://dx.doi.org/10.1136/jmg.2005.038331
18. Weischer M, Heerfordt IM, Bojesen SE, Eigentler T, Garbe C, Rocken M, et al. CHEK2*1100delC and risk of malignant melanoma: Danish and German studies and meta-analysis. J Invest Dermatol. 2012;132:299–303. http://dx.doi.org/10.1038/jid.2011.303
19. Złowocka E, Cybulski C, Górski B, Dębniak T, Słojewski M, Wokołorczyk D, et al. Germline mutations in the CHEK2 kinase gene are associated with an increased risk of bladder cancer. Int J Cancer. 2008;122:583–6. http://dx.doi.org/10.1002/ijc.23099
20. Näslund-Koch C, Nordestgaard BG, Bojesen SE. Increased risk for other cancers in addition to breast cancer for CHEK2*1100delC heterozygotes estimated from the Copenhagen general population study. J Clin Oncol. 2016 Apr 10;34(11):1208–16. http://dx.doi.org/10.1200/JCO.2015.63.3594
21. Szymanska-Pasternak J, Szymanska A, Medrek K, Imyanitov EN, Cybulski C, Gorski B, et al. CHEK2 variants predispose to benign, borderline and low-grade invasive ovarian tumors. Gynecol Oncol 2006;102(3):429–31. http://dx.doi.org/10.1016/j.ygyno.2006.05.040
22. Tołoczko-Grabarek A, Trubicka J, Lubiński J. Genetyka kliniczna nowotworów nerek. Genetyka kliniczna nowotworów 2016. Monografia pod redakcją Jana Lubińskiego. Print Group Sp zoo. Szczecin 2016, p. 1–15.
23. Ge Y, Wang Y, Shao W, Jin J, Du M, Ma G, et al. Rare variants in BRCA2 and CHEK2 are associated with the risk of urinary tract cancers. Sci Rep. 2016 Sep 16;6:33542. http://dx.doi.org/10.1038/srep33542
24. Ghatalia P, Yang ES, Lasseigne BN, Ramaker RC, Cooper SJ, Chen D et al. Kinase gene expression profiling of metastatic clear cell renal cell carcinoma tissue identifies potential new therapeutic targets. PLoS One. 2016 Aug 30;11(8):e0160924. http://dx.doi.org/10.1371/journal.pone.0160924
25. Apostolou P, Papasotiriou I. Current perspectives on CHEK2 mutations in breast cancer. Breast Cancer (Dove Med Press). 2017; 9: 331–335.